Physician profile
William Hood
NPI 1952539553
$1,993.76
in general payments reported to CMS, 2019-2025
25 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $360 · 2021: $327 · 2022: $229 · 2023: $171 · 2024: $195 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.23 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $448.18 | 2019-2022 | |
| Janssen Biotech, INC. | $223.55 | 2019-2022 | |
| Ucb, INC. | $91.56 | 2019-2020 | |
| Gilead Sciences, INC. | $81.11 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.28 | 2019-2020 | |
| Ardelyx, INC. | $51.46 | 2024-2025 | Ibsrela |
| Allergan, INC. | $47.71 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $44.46 | 2019-2021 | |
| Boston Scientific Corporation | $43.74 | 2023-2025 | General - Hemostasis |
| Aimmune Therapeutics, INC. | $36.66 | 2024 | |
| Nestle Healthcare Nutrition INC. | $32.49 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $30.72 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $29.41 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $28.64 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $26.30 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $23.63 | 2023 | Dificid |
| Vivus LLC | $23.33 | 2024 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $22.94 | 2024 | Dupixent |
| Celgene Corporation | $14.62 | 2022 | |
| Daiichi Sankyo INC. | $14.03 | 2020 | |
| Shire North American Group INC | $13.28 | 2019 | |
| Axonics, INC. | $12.94 | 2023 | Axonics |
| Evoke Pharma, INC. | $11.32 | 2021 | |
| Ambu INC. | $10.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.